Boundless Bio (Nasdaq: BOLD) announced that President and Chief Executive Officer Zachary Hornby will participate in a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida at 11:20 a.m. ET.
A live webcast and archived replay will be accessible via the company’s Investors Events & Presentations page for remote viewing.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – BOLD
+0.88%
+0.88%Session close to close
In the Mar 4 session, BOLD gained 0.88%, reflecting a mild positive market reaction.
This announcement highlights another investor-relations touchpoint as Boundless Bio’s CEO participat...
Analysis
This announcement highlights another investor-relations touchpoint as Boundless Bio’s CEO participates in a fireside chat at the Leerink Global Healthcare Conference. It follows recent scientific and financial disclosures, including Q3 2025 cash of $117.6M supporting operations into 1H 2028 and advancement of the BBI‑940 program. Investors may watch for presentation materials, webcast commentary, and upcoming clinical or regulatory milestones to better gauge how conference visibility complements the company’s broader development strategy.
Key Figures
Share price:$1.13Daily move:-2.59%52-week range:$0.9612–$1.9126+5 more
8 metrics
Share price$1.13Pre-news current price for BOLD
Daily move-2.59%Price change over prior 24 hours
52-week range$0.9612–$1.912652-week low and high before this news
Market cap$25,967,309Equity value prior to conference announcement
Cash balance$117.6MCash, equivalents and short-term investments as of Sept 30, 2025
Cash runwayInto 1H 2028Management-stated operating runway from Q3 2025 filings
FMR ownership12.0%Beneficial ownership of BOLD common stock as of 12/31/2025
Fidelity Growth Pool stake5.5%Fidelity Growth Company Commingled Pool ownership as of 12/31/2025
Announced AACR‑NCI‑EORTC poster on BBI‑825 and BBI‑355 in oncogene amplified cancers.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Reactions to news skew toward divergence, with several positive or neutral updates followed by negative price moves.
Recent Company History
This announcement continues a pattern of conference-focused communications, following fireside chats at Guggenheim on Feb 12, 2026 and Piper Sandler on Dec 3, 2025. In between, BOLD highlighted advancement of BBI-940 and an extended cash runway and earlier reported Q3 2025 results showing $117.6M in cash supporting operations into the first half of 2028. The AACR‑NCI‑EORTC poster in October 2025 showcased combination data for BBI‑355 and BBI‑825. Today’s Leerink participation fits the ongoing visibility and investor-relations cadence rather than a new clinical or financial inflection.
Key Terms
extrachromosomal dna, ecdna, oncogene, webcast
4 terms
extrachromosomal dnamedical
"clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology"
Extrachromosomal DNA are pieces of genetic material found inside a cell but outside the cell’s main chromosomes, often as small circular or loose fragments. They can carry copies of genes that drive cell growth and can make tumors behave differently or resist treatments, so for investors they matter because they can influence how effective drugs, diagnostics, or therapies will be and therefore alter risk, timelines and potential value in biotech and healthcare deals.
ecdnamedical
"interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies"
Extrachromosomal DNA (ecDNA) are small, circular pieces of DNA that sit outside a cell’s normal chromosomes and often carry extra copies of genes that drive cell growth. Think of them as sticky notes with repeat instructions that can make a cell behave aggressively; for investors, ecDNA matters because it creates unique disease biology that can change how cancers are diagnosed, how drugs work, and which therapies or diagnostics gain commercial value.
An oncogene is a gene that, when altered or overly active, pushes a cell to grow and divide uncontrollably — like a car’s gas pedal stuck down. Investors care because drugs, tests, or therapies that block or detect oncogene activity can become valuable products, drive clinical trial outcomes, affect regulatory approval, and change a company’s revenue prospects tied to cancer diagnostics and treatments.
webcasttechnical
"A live and archived webcast of the session will be accessible"
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Leerink Global Healthcare Conference.
The fireside chat session is scheduled for Wednesday, March 11, in Miami, Florida at 11:20 a.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website.
About Boundless Bio Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. Boundless Bio’s research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Boundless Bio is developing BBI-940, a potentially first-in-class oral, selective, degrader of Kinesin as an ecDNA-directed therapeutic candidate (ecDTx). Boundless Bio is headquartered in San Diego, CA.
When is Boundless Bio (BOLD) presenting at the Leerink Global Healthcare Conference?
The fireside chat is scheduled in Miami for Wednesday, March 11, 2026 at 11:20 a.m. ET. According to Boundless Bio, CEO Zachary Hornby will participate and a live webcast plus archived replay will be available on the investor site.
How can investors watch the Boundless Bio (BOLD) Leerink fireside chat?
Investors can watch via a live webcast and later view an archived replay on the company's investor site. According to Boundless Bio, the webcast will be posted under Events & Presentations in Investors and available for on-demand replay.
Who from Boundless Bio (BOLD) will speak at the Leerink Global Healthcare Conference?
Zachary Hornby, President and Chief Executive Officer, will represent Boundless Bio at the fireside chat. According to Boundless Bio, Hornby will discuss the company's ecDNA-focused oncology programs and development strategy during the March 11 session.
Will there be a replay of the Boundless Bio (BOLD) Leerink presentation and where will it be posted?
Yes. A replay will be archived and available on Boundless Bio's Investors 'Events & Presentations' page after the live session. According to Boundless Bio, the archived webcast will remain accessible for on-demand viewing to investors who cannot attend the Miami event.
Does the Boundless Bio (BOLD) conference announcement include new clinical readouts or regulatory news?
The announcement confirms a conference presentation but does not disclose new regulatory decisions or clinical trial readouts. According to Boundless Bio, the session is a fireside chat focused on company programs; no specific efficacy data or approvals were announced to date.
